Marksans Pharma Limited has informed the Exchange regarding Appointment of Mr. Srinivas Mishra as Non- Executive Independent Director of the company w.e.f. April 01, 2025.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's board approved audited financial results for Q4 and FY ended March 31, 2025, with auditor MSKA & Associates giving an unmodified opinion. On a consolidated basis, revenue from operations grew about 20% year-on-year to Rs. 2,622.8 crore, while profit after tax rose roughly 21.5% to Rs. 382.6 crore; standalone PAT jumped about 40.8% to Rs. 188.3 crore on Rs. 1,174.4 crore revenue. The board recommended a final dividend of Rs. 0.80 per share (80% on Re. 1 face value) for FY25, subject to shareholder approval at the upcoming AGM. It also appointed Mr. Srinivas Mishra (ex-SBI Deputy GM, Corporate Banking & Risk) as a Non-Executive Independent Director for 5 years from April 1, 2025, and approved amendments to the Marksans Employees Stock Option Scheme 2024, which has a pool of 23 lakh options.
Strong FY25 earnings growth, a healthy dividend payout, and an unchanged auditor reinforce confidence in the business; the new independent director adds banking and risk expertise to the board, while ESOP amendments are dilution-neutral until options are granted.